APA

Sorenson E. J., Windbank A. J., Mandrekar J. N., Bamlet W. R., Appel S. H., Armon C., Barkhaus P. E., Bosch P., Boylan K., David W. S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C. A., McCluskey L. F., Nash S., Newman D. S., Pascuzzi R. M., Pioro E., Sams L. J., Scelsa S., Simpson E. P., Subramony S. H., Tiryaki E. & Thornton C. A. (20081218). Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. : Neurology.

Chicago

Sorenson E J, Windbank A J, Mandrekar J N, Bamlet W R, Appel S H, Armon C, Barkhaus P E, Bosch P, Boylan K, David W S, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano C A, McCluskey L F, Nash S, Newman D S, Pascuzzi R M, Pioro E, Sams L J, Scelsa S, Simpson E P, Subramony S H, Tiryaki E and Thornton C A. 20081218. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. : Neurology.

Harvard

Sorenson E. J., Windbank A. J., Mandrekar J. N., Bamlet W. R., Appel S. H., Armon C., Barkhaus P. E., Bosch P., Boylan K., David W. S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C. A., McCluskey L. F., Nash S., Newman D. S., Pascuzzi R. M., Pioro E., Sams L. J., Scelsa S., Simpson E. P., Subramony S. H., Tiryaki E. and Thornton C. A. (20081218). Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. : Neurology.

MLA

Sorenson E J, Windbank A J, Mandrekar J N, Bamlet W R, Appel S H, Armon C, Barkhaus P E, Bosch P, Boylan K, David W S, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano C A, McCluskey L F, Nash S, Newman D S, Pascuzzi R M, Pioro E, Sams L J, Scelsa S, Simpson E P, Subramony S H, Tiryaki E and Thornton C A. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. : Neurology. 20081218.